Birth after the injection of sperm and the cytoplasm of tripronucleate zygotes into metaphase ii oocytes in patients with repeated implantation failure after assisted fertilization procedures

Huang, Chun‐Chia; Cheng, Tzu‐Chun; Chang, Han-Hsin; Chang, Ching-Chien; Chen, Chung-I; Liu, Jiaen; Lee, Maw‐Sheng

doi:10.1016/s0015-0282(99)00309-x

Cited by 60 publications

(48 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Success however depends on the unpredictable nature of mitochondrial segregation during fetal development and which organs will eventually have levels of mutant mtDNA above the disease threshold. Ooplasmic transfer has been reported in patients that had previously experienced failed embryonic development, where the donated portion of ooplasm is thought to provide mitochondria and other factors that support developmental competency (Van Blerkom et al, 1998, Huang et al, 1999, Jacobs et al, 2006). Of concern is the finding in some studies of an increased incidence of chromosomal abnormalities and birth defects post ooplasmic transfer (Brown et al, 2006, Jacobs et al, 2006).…”

Section: Mitochondrial Transfer Techniquesmentioning

confidence: 99%

Mitochondrial transfer: Implications for assisted reproductive technologies

Reznichenko

Huyser

Pepper

2016

Applied & Translational Genomics

View full text Add to dashboard Cite

The use of mitochondrial transfer as a clinic procedure is drawing closer to reality. Here we provide a detailed overview of mitochondrial transfer techniques – both established and recent – including pronuclear, spindle, ooplasmic and blastomere transfer. Reasons as to why some techniques are more suitable for the prevention of mitochondrial DNA disease than others, as well as the advantages and disadvantages of each methodology, are discussed. The possible clinical introduction of these techniques has raised concerns about the adverse effects they may have on resultant embryos and offspring. Success rates of each technique, embryo viability and developmental consequences post mitochondrial transfer are addressed through analysis of evidence obtained from both animal and human studies. Counterarguments against potential mitochondrial-nuclear genome incompatibility are also provided. Additional clinical applications of mitochondrial transfer techniques are discussed. These include the rescue or enhancement of fertility in women of advanced maternal age or those suffering from diabetes. An alternative to using mitochondrial DNA transfer for germ line therapies is the therapeutic use of somatic cell nuclear transfer for the generation of personalised stem cells. Although ethically challenging, this method could offer patients already suffering from mitochondrial DNA diseases a novel treatment option.

show abstract

Section: Mitochondrial Transfer Techniquesmentioning

confidence: 99%

Mitochondrial transfer: Implications for assisted reproductive technologies

Reznichenko

Huyser

Pepper

2016

Applied & Translational Genomics

View full text Add to dashboard Cite

show abstract

“…Over the past 25 years, an increasing body of clinical and preclinical data has demonstrated that the decline in egg quality is largely due to a reduction in energy production [8][9][10][11]. In the 1990s, there were attempts at improving egg and embryo quality by injecting cytoplasm from young, healthy, donor eggs into the eggs of women with a history of reproductive failures [12][13][14]. The cytoplasm injection procedure involved the injection of third-party mitochondria obtained from younger donor eggs and resulted in the birth of approximately 50 seemingly healthy babies [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…In the 1990s, there were attempts at improving egg and embryo quality by injecting cytoplasm from young, healthy, donor eggs into the eggs of women with a history of reproductive failures [12][13][14]. The cytoplasm injection procedure involved the injection of third-party mitochondria obtained from younger donor eggs and resulted in the birth of approximately 50 seemingly healthy babies [12][13][14]. This groundbreaking work was not pursued as more study was required [11].…”

Section: Introductionmentioning

confidence: 99%

The AUGMENTSM Treatment: Physician Reported Outcomes of the Initial Global Patient Experience

Fakih¹,

Shmoury²,

Szeptycki³

et al. 2015

JFIV Reprod Med Genet

101

View full text Add to dashboard Cite

IntroductionInfertility treatment prior to 1978 proved challenging to both patients and their physicians. The birth of Louise Brown through in vitro fertilization (IVF) was the result of decades-long research in both the basic and clinical sciences and followed hundreds of failed attempts at human IVF [1]. With IVF's successful introduction, related and supportive technologies soon emerged including IVF and the use of donor eggs, cryopreservation and frozen embryo transfer (FET), gamete intra-fallopian transfer (GIFT), zygote intra-fallopian transfer (ZIFT), intra-cytoplasmic sperm injection (ICSI) and less invasive procedures aided by enhancements in equipment, such as transvaginal ultrasound guided oocyte retrieval. It may be hard to recall now that technologies such as IVF, the use of donor eggs, and ICSI were, at first, controversial but so successful in improving outcomes that they were most often adopted into clinical practice without any demonstrated benefit in randomized controlled clinical trials [2].Despite the technical enhancements introduced over time that have resulted in unprecedented cumulative IVF pregnancy rates, a significant percentage of women continue to fail repeated attempts at IVF. While cumulative pregnancy rates increase with increasing cycle number (approximately 75% of women will achieve a live birth by the sixth IVF cycle), per cycle IVF success rates tend to decrease with increasing cycle number. The age blended probability of a live birth is approximately 25% in a woman's first cycle (range [9-33%]), 20% per cycle during her second and third cycles and decreases to less than 20% per cycle during cycles four through six [3]. IVF success rates drop dramatically as women age. Therefore, a patient population exists that will fail to respond to all lines of treatment, including repeated cycles of IVF. For this patient population, IVF using a donor egg or adoption have, until recently, represented the only remaining option(s) [4].The causes of repeated IVF failure are often complex and poorly understood. In contrast, the decrease in fertility observed in women with increasing maternal age has been attributed to a decline in egg and embryo quality as well as increased rates of aneuploidy [5]. Other causes of poor egg/embryo quality beyond age-related factors include medical conditions such as type II diabetes, obesity, polycystic ovary syndrome (PCOS), as well as other genetic and environmental factors [6,7]. Over the past 25 years, an increasing body of clinical and preclinical data has demonstrated that the decline in egg quality is largely due to a reduction in energy production [8][9][10][11]. In the 1990s, there were attempts at improving egg and embryo quality by injecting cytoplasm from young,

show abstract

“…It has been suggested that the introduction of a small amount of ooplasm from a healthy donor oocyte might rescue the function of oocytes that may have certain ooplasm deficiencies [1]. Ooplasm transfer has been attempted in humans and a few pregnancies have resulted [2][3][4]. However, it is not yet fully clear how ooplasm transfer works.…”

Section: Introductionmentioning

confidence: 99%